KF
MCRB icon

Krilogy Financial’s Seres Therapeutics MCRB Stock Holding History

Krilogy Financial’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20
Closed -$3K – 452
2018
Q3 		$3K Buy
+20
New +$3.24K ﹤0.01% 683
2018
Q2 		– Sell
-20
Closed -$3K – 431
2018
Q1 		$3K Hold
20
– – ﹤0.01% 657
2017
Q4 		$4K Buy
+20
New +$4.11K ﹤0.01% 631

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Krilogy Financial's MCRB Position: Q4 2018 in Review

Krilogy Financial sold out of Seres Therapeutics (MCRB) in Q4 2018, closing a stake of 20 shares — an estimated $3K sold.

Krilogy Financial first reported a position in MCRB in Q4 2017 and held it in 3 quarters. The position peaked at $4K in Q4 2017. 70 funds tracked by Wall St. Rank hold MCRB as of Q4 2018.

  • Krilogy Financial reported no remaining Seres Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Krilogy Financial sold 20 Seres Therapeutics shares in Q4 2018, an estimated $3K.
  • Krilogy Financial first reported a position in Seres Therapeutics in Q4 2017 and held it in 3 quarters.
  • Krilogy Financial's Seres Therapeutics position peaked at $4K in Q4 2017.
  • 70 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.